Mainz Biomed BVNASDAQ: MYNZ

BERKELEY, Calif. and MAINZ, Germany, July 02, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Results from pooled study represents the third consecutive confirmation of the consistently good performance of Mainz Biomed's mRNA biomarkers to detect CRC and precancerous lesions BERKELEY, Calif. and MAINZ, Germany, June 03, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Key Findings: 92.3% Sensitivity for Colorectal Cancer, 82.3% for Advanced Precancerous Lesions Poster presentation showing new data on 690 subjects including previously unexamined and unreported samples from the pooled ColoFuture and eAArly DETECT studies utilizing the mRNA biomarkers, FIT test, and a proprietary AI Algorithm BERKELEY, Calif. and MAINZ, Germany, May 28, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed Presented Industry Leading Results: 97% Sensitivity for Colorectal Cancer, 82% for Advanced Precancerous Lesions The eAArly DETECT results demonstrated that within the advanced precancerous lesion patients, 100% of those patients with high grade dysplasia were detected The Company's mission is to transform current colorectal cancer screening practices, and ultimately to reduce cancer mortality rates worldwide by shifting from cancer detection to cancer prevention BERKELEY, Calif. and MAINZ, Germany, May 20, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed NV (MYNZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

BERKELEY, Calif. and MAINZ, Germany, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.

Mainz Biomed (NASDAQ: MYNZ ) stock is on the move Wednesday after the molecular genetics cancer diagnostic company shared results from a colorectal cancer screening test campaign. The company held this screening test campaign with the help of partner Zöller-Kipper GmbH.

Clinical trial evaluating the Company's novel mRNA biomarkers demonstrated sensitivity for colorectal cancer of 94% with specificity of 97% and advanced adenoma sensitivity of 81% Pulsus Group's 4th International Conference on Gastroenterology, to be held in Paris, France, brings together world-renowned speakers to share discoveries and receive updates in the field of Gastroenterology BERKELEY, Calif. and MAINZ, Germany, Sept.